Balyasny Asset Management Reports 9.99% Stake in SAB Biotherapeutics, Inc.

Balyasny Asset Management L.P. (BAM) and its affiliated reporting persons, including Dmitry Balyasny, have filed a Schedule 13G indicating a significant new position in SAB Biotherapeutics, Inc. (SABS). As of March 31, 2026, the reporting persons collectively beneficially own 5,089,939 shares of common stock, representing 9.99% of the company's outstanding shares. This ownership includes 3,760,439 shares held directly and 1,329,500 shares issuable upon the exercise of warrants. The filing notes that the warrants are subject to a Beneficial Ownership Limitation blocker, which prevents the reporting persons from exercising them if it would result in owning more than 9.99% of the outstanding shares. The shares are held across investment vehicles managed by BAM, including Atlas Diversified Master Fund, Ltd and Atlas Private Holdings (Cayman) Ltd. The reporting persons have certified that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.